(Q22241376)

PubMed

7 February 2023

2

Bart C Jacobs

Bart C

Jacobs

1 reference

PubMed

7 February 2023

Christa Walgaard

1

Christa

Walgaard

1 reference

PubMed

21352072

Expert Opinion on Emerging Drugs

7 February 2023

language of work or name

English

0 references

publication date

March 2011

0 references

published in

0 references

volume

16

0 references

issue

1

0 references

page(s)

105-120

0 references

cites work

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

Immunotherapy for Guillain-Barre syndrome: a systematic review

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

Structure of and influence of a tick complement inhibitor on human complement component 5

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

An Unusual Variant of Acute Idiopathic Polyneuritis (Syndrome of Ophthalmoplegia, Ataxia and Areflexia)

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2011.531699

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Pain in Guillain-Barre syndrome: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Ganglioside complexes as new target antigens in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Supportive care for patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Controlled trial prednisolone in acute polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

A clinical prognostic scoring system for Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Guillain-Barré syndrome: incidence and mortality rates in US hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Plasmapheresis for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Case-control study of thromboembolic events associated with IV immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Economic cost of Guillain-Barré syndrome in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

The economic burden of Campylobacter-associated Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Health burden in the Netherlands due to infection with thermophilic Campylobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Conduction block in acute motor axonal neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

How to assess new drugs for neuropathies: advances in trial design and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Statistical assessment of ordinal outcomes in comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Eculizumab for paroxysmal nocturnal haemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

The immunobiology of Guillain-Barré syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Modafinil for the treatment of multiple sclerosis-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Pathology of the motor-sensory axonal Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

No Association Between Immunization and Guillain-Barré Syndrome in the United Kingdom, 1992 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Shortage of human intravenous immunoglobulin—reasons and possible solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

Unusual clinical variants and signs in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Acute motor conduction block neuropathy or acute multifocal motor neuropathy: an attempt at a nosological systematization

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Psychosocial dysfunction in the first year after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Nerve conduction studies in relation to residual fatigue in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Origin of ganglioside complex antibodies in Guillain–Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Small fibre impairment predicts neuropathic pain in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Long-term impact on work and private life after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Distribution of inducible nitric oxide synthase and tumor necrosis factor-alpha in the peripheral nervous system of Lewis rats during ascending paresis and spontaneous recovery from experimental autoimmune neuritis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Treatment of Guillain-Barré syndrome with high-dose gammaglobulin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Infections and course of disease in mild forms of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

Safety of intravenous immunoglobulin treatment

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531699

7 January 2021

10.1517/14728214.2011.531699

Identifiers

DOI

0 references